Does Baseline Cognitive Function Predict the Reduction Rate in HDRS-17 Total Scores in First-Episode, Drug-Naïve Patients with Major Depressive Disorder?
Qingyan Jiao,Yeqing Dong,Xiaojuan Ma,Shiyi Ji,Xinyu Liu,Jian Zhang,Xia Sun,Dazhi Li,Xingguang Luo,Yong Zhang
DOI: https://doi.org/10.2147/ndt.s453447
IF: 2.989
2024-02-23
Neuropsychiatric Disease and Treatment
Abstract:Qingyan Jiao, 1, &ast Yeqing Dong, 2, &ast Xiaojuan Ma, 3 Shiyi Suzy Ji, 4 Xinyu Liu, 1 Jian Zhang, 1 Xia Sun, 1 Dazhi Li, 1 Xingguang Luo, 5 Yong Zhang 1 1 Unit of Bipolar Disorder, Tianjin Anding Hospital, Tianjin, 300222, People's Republic of China; 2 Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, 300222, People's Republic of China; 3 Tianjin Medical College, Tianjin, 300222, People's Republic of China; 4 Teachers College, Columbia University, New York, NY, USA; 5 Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 06511, USA &astThese authors contributed equally to this work Correspondence: Yong Zhang, Unit of Bipolar Disorder, Tianjin Anding Hospital, 13 Liulin Road, Hexi District, Tianjin, 300222, People's Republic of China, Tel/Fax +86 22 8818 8258, Email Purpose: Major depressive disorder (MDD) is associated with worse cognitive functioning. We aim to examine the association between baseline cognitive functioning and the reduction rate in HDRS-17 total scores and to highlight the predictors of the reduction rate in HDRS-17 total scores in MDD with first-episode, drug-naïve (FED) patients. Patients and Methods: Ninety FED patients were recruited consecutively and evaluated using the 17-item Hamilton Depression Rating Scale (HDRS-17), the 14-item Hamilton Anxiety Scale (HAMA-14), the Functioning Assessment Short Test (FAST) and the MATRICS Consensus Cognitive Battery (MCCB) at baseline and again at week 8. Results: Eighty-four FED patients completed the study. Comparison showed that response group had significantly higher T scores in TMT-A, BACS-SC, WMS-III, BVMT-R, MSCEI and CPT-IP, but showed significantly lower scores in FAST total scores including autonomy, occupational functioning, cognitive functioning, interpersonal relationship than non- response group (all p's < 0.05). Partial correlation analysis also found that the reduction rate in HDRS-17 total scores could be negatively associated with autonomy, cognitive functioning and interpersonal relationship domains as well as total FAST scores, also was further positively associated with T-scores of BACS-SC, CPT-IP and MSCEI in MCCB, even when accounting for potential confounders. Furthermore, the levels of cognitive function domain, autonomy domain in FAST, and BACS-SC, CPT-IP in MCCB may predict the reduction rate in HDRS-17 total scores in FED patients (all p's < 0.05). Conclusion: Our findings underscore significant correlations between baseline functioning and the reduction rate in HDRS-17 total scores in FED patients. Moreover, better baseline cognitive function, autonomy, speed of processing and attention/vigilance are more likely to predict patients' response to antidepressant treatment, indicating pre-treatment better cognitive functioning may be predictors to treatment response in FED. Keywords: FED, FAST, MCCB, treatment response, the reduction rate in HDRS-17 total scores Major depressive disorder (MDD) is a chronic, recurrent disease that affects 350 million people worldwide annually. Depression is estimated to be the second leading chronic cause of disability. 1,2 According to the World Mental Health Survey, the 12-month prevalence rates for major depressive episodes (MDE) vary internationally, from 2.2% in Japan to 10.4% in Brazil, with averages of 5.5% in developed countries and 5.9% in developing ones. 3 In China, the lifetime and 12-month prevalence have been documented at 3.9% and 2.3%, respectively. 4 MDD, a common psychiatric disorder, is characterized by heterogeneous clinical performance and functional impairment. Impairments of social and neurocognitive function have been evidenced in MDD patients. 5,6 Further explorations determined that work capacity, home management, social activity, and personal relationships could be closely related to depressive symptoms. 7 MDD patients also continue to present significant moderate cognitive deficits in executive function, memory and attention even in remission, suggesting that cognitive impairment occurs separately from depressive symptoms. 8 Significant cognitive deficits are already identifiable during a FED, with some functions showing persistent impairment upon remission. Clinicians must consider cognitive impairment alongside mood symptoms to ensure functional recovery from the MDD, especially first-episode, drug-naïve (FED) patients. 9,10 Previous studies have revealed that this persistent and clinically significant functio -Abstract Truncated-
psychiatry,clinical neurology